A B S T R A C TWe present a novel bioaerosol sampling system based on a wet-cyclone for real-time and continuous monitoring of airborne microorganisms. The Automated and Real-time Bioaerosol Sampler based on Wet-cyclone (ARBSW) continuously collects bioaerosols in a liquid medium and delivers the samples to a sensing device using a wireless remote control system. Based on a high air-to-liquid-flow-rate ratio (∼ 1.4 × 10 5 ) and a stable liquid thin film within a wet-cyclone, the system achieved excellent sampling performance as indicated by the high concentration and viability of bioaerosols (> 95% collection efficiency for > 0.5-μm-diameter particles, > 95% biological collection efficiency for Staphylococcus epidermidis and Micrococcus luteus). Furthermore, the continuous and real-time sampling performance of the ARBSW system under test-bed conditions and during a field test demonstrated that the ARBSW is capable of continuously monitoring bioaerosols in real time with high sensitivity. Therefore, the ARBSW shows promise for continuous real-time monitoring of bioaerosols and will facilitate the management of bioaerosol-related health and environmental issues.

Real-time on-site monitoring of bioaerosols in an air environment is important for preventing various adverse health effects including respiratory diseases and allergies caused by bioaerosols. Here, we report the development of an on-site automated bioaerosol-monitoring system (ABMS) using integrated units including a wet-cyclone bioaerosol sampler, a thermal-lysis unit for extracting adenosine triphosphate (ATP), an ATPdetection unit based on the immobilization of luciferase/luciferin for bioluminescence reactions, and a photomultiplier tube-based detector. The performance of the bioaerosol detection system was verified using Escherichia coli (E. coli) as a model source. Each unit was optimized to process ∼9.6 × 10 5 times the concentrated ratio of collected bioaerosol samples, using a 3 min lysis time to extract ATP, and has a detection limit of ∼375 colony-forming units (CFUs)/mL with more than 30 days of stability for the immobilizedluciferase/luciferin detection unit supported by a glass-fiber conjugation pad. After the integration of all units, the ABMS achieved E. coli bioaerosol monitoring with continuous detection at 5 min intervals and a minimum detection limit of ∼130 CFU/m air 3 . Furthermore, the rapid responsivity and stable operation performance of the ABMS under test-bed conditions and during a field test demonstrated that the ABMS is capable of continuously monitoring bioaerosols in real-time with high sensitivity. The monitoring system developed here with immobilization strategies for bioluminescence reactions triggered by ATP extracted from collected bioaerosol samples using a simple heat-lysis method may help establish sustainable platforms to obtain stable signals for the real-time detection of bioaerosols on-site.

Background The development of dermatitis on face and neck, which was not described in phase 3 clinical trials, has been reported in the literature in patients treated with dupilumab. Little is known regarding the causes or defining features of the facial dermatitis. Objectives We conducted surveys of consecutive patients with AD on dupilumab to describe its clinical features, morphology and aetiology. Methods A multi‐centre prospective cohort study was conducted from 1 January 2020, to 31 December 31 2020. A total of 162 patients under dupilumab treatment were asked to complete a questionnaire and patients were evaluated by dermatologists. Results Of all 162 patients, 137 (84.6%) patients reported pre‐existing facial dermatitis prior to dupilumab therapy. One hundred and twenty‐one (88.3%) patients with pre‐existing facial dermatitis reported improvement of their facial dermatitis with dupilumab therapy, nine (6.6%) patients reported no change after the treatment and seven (4.3%) patients of them got worse after the treatment (exacerbation group). Of 25 patients who reported no pre‐existing active facial dermatitis, six (24%) patients reported new‐onset facial erythema after the starting dupilumab therapy (new‐onset group). A large proportion of the patients in both the exacerbation (86%) and new‐onset groups (67%) had a history of facial TCS use. Both groups showed similar clinical manifestations and distribution with few differences. Conclusions The vast majority of patients treated with dupilumab in academic institutions from Korea and the United States experienced improvement in their facial dermatitis with dupilumab therapy. A small proportion of patients had new onset and exacerbation. Although the mechanisms of this adverse event remain unclear, steroid withdrawal should be considered as a diagnosis of the erythema in some patients.